A study to evaluate the effect of Golimumab Versus Tocilizumab in the treatment of Severe and Refractory Juvenile Idiopathic Arthritis (JIA)- uveitis

Trial Profile

A study to evaluate the effect of Golimumab Versus Tocilizumab in the treatment of Severe and Refractory Juvenile Idiopathic Arthritis (JIA)- uveitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Golimumab (Primary) ; Tocilizumab; Tocilizumab
  • Indications Juvenile rheumatoid arthritis; Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top